NASDAQ · PTCT

PTC Therapeutics, Inc.

Healthcare · Biotechnology

$62.34

Down-$0.19 (-0.30%)

Updated Sep 24, 2026, 3:12 PM

SID Score

4.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap: 6.05B
P/E ratio: 7.87
Dividend yield: 0.00%
52-week range: $60.28 – $90.87
Volume: 1.1M
Avg. volume: 1.55M

Price performance

PTCT price history

1M range · 20 trading sessions · Daily adjusted prices

Last close: $62.34
Period change: -14.24%
Period low: $62.34
Period high: $72.69

Daily close

View OHLC price history

PTCT OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Sep 23, 2026	$65.80	$66.1523	$62.24	$62.34	1.1M
Sep 22, 2026	$66.24	$66.58	$65.36	$65.96	1.31M
Sep 21, 2026	$65.93	$66.21	$64.99	$65.26	1.09M
Sep 18, 2026	$68.00	$68.005	$65.18	$65.37	3.86M
Sep 17, 2026	$68.84	$68.84	$67.22	$68.00	1.12M
Sep 16, 2026	$65.99	$67.90	$65.795	$67.59	1.4M
Sep 15, 2026	$66.51	$66.54	$65.06	$65.65	1.03M
Sep 14, 2026	$67.09	$67.99	$65.91	$66.48	1.02M
Sep 11, 2026	$67.80	$68.48	$65.91	$66.06	792.89K
Sep 10, 2026	$66.84	$67.78	$66.47	$67.37	1.01M
Sep 9, 2026	$68.08	$68.84	$67.50	$67.57	1.07M
Sep 8, 2026	$67.81	$70.08	$67.475	$68.81	1.12M
Sep 4, 2026	$70.62	$71.405	$69.26	$69.30	673.54K
Sep 3, 2026	$71.76	$71.97	$70.55	$71.40	654.52K
Sep 2, 2026	$71.15	$72.68	$69.835	$71.79	902.58K
Sep 1, 2026	$69.42	$70.84	$69.05	$70.56	691.02K
Aug 31, 2026	$69.98	$70.42	$68.755	$69.54	841.1K
Aug 28, 2026	$71.08	$71.49	$69.61	$70.09	692.68K
Aug 27, 2026	$72.11	$72.66	$70.91	$71.81	746.33K
Aug 26, 2026	$73.18	$73.525	$71.81	$72.69	533.67K

Latest PTCT news

The latest Smart Investors Daily articles mentioning PTCT.

analystAug 17, 2026

Barclays Reiterates Overweight Rating on PTC Therapeutics, Inc. (PTCT)

analystAug 14, 2026

Wells Fargo Reiterates Overweight Rating on PTC Therapeutics, Inc. (PTCT)

earningsJul 30, 2026

PTC Therapeutics (PTCT) Beats Q2 Earnings Estimates by $0.61

Latest PTCT news

The latest Smart Investors Daily articles mentioning PTCT.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

PTCT research

Overview

Company profile and research snapshot.

Company profile

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: $74.83
Implied upside: —
Analysts: —

PTCT recent ratings
Date	Firm	Rating	Target
Sep 22, 2026	Cantor Fitzgerald	Overweight	—
Aug 14, 2026	Barclays	Overweight	—
Aug 13, 2026	Wells Fargo	Overweight	—
Jul 31, 2026	Morgan Stanley	Overweight	—
Jul 31, 2026	Wells Fargo	Overweight	—

Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 20, 2026

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68. Recent trading has been choppy for PTC Therapeutics, with the share price down 3.9% over the last session to $65.37 and weaker momentum over the past quarter. However, the 3-year total shareholder return of 173.3% and 5-year total shareholder return of 66.4% still reflect a materially stronger long-run...

Yahoo · Sep 17, 2026

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the

SeekingAlpha · Sep 15, 2026